Canine gonadal tissues-derived mesenchymal stem cell therapy for early myxomatous mitral valve disease in dogs: the SPRING study, a prospective comparative pilot study
Mesenchymal stem cells (MSCs) are multipotent stromal cells that can promote tissue repair and exert immunomodulatory and anti-inflammatory effects. Myxomatous mitral valve disease (MMVD) is primarily degenerative, and routine pharmacological treatment is not recommended at stage B1. This exploratory study assessed changes in serum transforming growth factor-β1 (TGF-β1) following systemic administration of allogeneic canine gonadal tissue-derived MSCs (GD-MSCs) in client-owned dogs with stage B1 MMVD, with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiographic measurements as secondary outcomes. The analyzed cohort comprised ten dogs, allocated according to owners’ treatment choices (MSC, n = 5; control, n = 5). Treated dogs received intravenous allogeneic GD-MSCs (1 × 10 6 cells/kg) at monthly intervals for four administrations and were followed for 6 months. Compared with controls, MSC-treated dogs showed greater decreases from baseline to six months in serum TGF-β1 ( p = 0.0317), NT-proBNP ( p = 0.0079), and body weight-normalized anterior mitral leaflet area ( p = 0.0079; Holm- and Bonferroni-adjusted p = 0.0238). The NT-proBNP mean-change difference was − 530.38 pmol/L (Welch 95% confidence interval − 846.19 to − 214.57), although absolute concentrations did not differ significantly between groups at either visit. Changes in body weight-normalized left ventricular end-diastolic internal diameter (LVIDDN) ( p = 0.0397) and vertebral left atrial size (VLAS) ( p = 0.0079) also decreased to a greater extent in the MSC group. GD-MSC administration was associated with six-month changes in circulating biomarkers and selected cardiac imaging measurements in dogs with stage B1 MMVD. These prospective comparative observations support further evaluation of MSCs in early MMVD, with larger randomized studies needed to determine whether the initial signals translate into sustained clinical benefit.
Authors
- So-Young Jeung (ORCID: https://orcid.org/0000-0002-5689-3608)
- Ga‐Hyun Lim (ORCID: https://orcid.org/0000-0001-7019-6246)
- Sung‐Soo Kim (ORCID: https://orcid.org/0000-0001-9480-8163)
- 정유진
- Sohee Lim
- Sun-Hye Song
Publication Details
- Journal
- BMC Veterinary Research
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s12917-026-06087-2
- Primary Topic
- Mesenchymal stem cell research
- Type
- article
- Field-Weighted Citation Impact
- 0.00